last_updated: 1406017858
is_oa: False
cited_by_posts_count: 2
images: {u'small': u'https://altmetric-badges.a.ssl.fastly.net/?size=64&score=2&types=tttttttt', u'large': u'https://altmetric-badges.a.ssl.fastly.net/?size=180&score=2&types=tttttttt', u'medium': u'https://altmetric-badges.a.ssl.fastly.net/?size=100&score=2&types=tttttttt'}
altmetric_id: 640494
subjects: [u'science', u'medicine']
published_on: 1331164800
title: Reduced Serotonin Reuptake Transporter (SERT) Function Causes Insulin Resistance and Hepatic Steatosis Independent of Food Intake.
cited_by_tweeters_count: 2
scopus_subjects: [u'Medicine', u'Health Sciences', u'Biochemistry, Genetics and Molecular Biology', u'Life Sciences', u'Agricultural and Biological Sciences']
issns: [u'1932-6203']
score: 1.25
altmetric_jid: 4f6fa5313cf058f6100043e3
pmid: 22412882
abstract: Serotonin reuptake transporter (SERT) is a key regulator of serotonin neurotransmission and a major target of antidepressants. Antidepressants, such as selectively serotonin reuptake inhibitors (SSRIs), that block SERT function are known to affect food intake and body weight. Here, we provide genetic evidence that food intake and metabolism are regulated by separable mechanisms of SERT function. SERT-deficient mice ate less during both normal diet and high fat diet feeding. The reduced food intake was accompanied with markedly elevated plasma leptin levels. Despite reduced food intake, SERT-deficient mice exhibited glucose intolerance and insulin resistance, and progressively developed obesity and hepatic steatosis. Several lines of evidence indicate that the metabolic deficits of SERT-deficient mice are attributable to reduced insulin-sensitivity in peripheral tissues. First, SERT-deficient mice exhibited beta-cell hyperplasia and islet-mass expansion. Second, biochemical analyses revealed constitutively elevated JNK activity and diminished insulin-induced AKT activation in the liver of SERT-deficient mice. SERT-deficient mice exhibited hyper-JNK activity and hyperinsulinemia prior to the development of obesity. Third, enhancing AKT signaling by PTEN deficiency corrected glucose tolerance in SERT-deficient mice. These findings have potential implications for designing selective SERT drugs for weight control and the treatment of metabolic syndromes.
schema: 1.5.4
cohorts: {u'pub': 2}
readers_count: 16
journal: PLoS ONE
publisher_subjects: [{u'scheme': u'era', u'name': u'Multidisciplinary'}]
details_url: http://www.altmetric.com/details.php?citation_id=640494
doi: 10.1371/journal.pone.0032511
abstract_source: pubmed
ads_id: 2012ploso...7e2511c
readers: {u'mendeley': 16, u'citeulike': 0, u'connotea': 0}
nlmid: 101285081
url: http://dx.doi.org/10.1371/journal.pone.0032511
context: {u'similar_age_journal_3m': {u'count': 2725, u'higher_than': 1437, u'pct': 52, u'rank': 1126, u'mean': 5.23196989721}, u'all': {u'count': 2291818, u'higher_than': 1265597, u'pct': 55, u'rank': 903035, u'mean': 4.8105653898216}, u'similar_age_3m': {u'count': 70297, u'higher_than': 42914, u'pct': 61, u'rank': 22873, u'mean': 3.9041783031751}, u'journal': {u'count': 49186, u'higher_than': 23933, u'pct': 48, u'rank': 22310, u'mean': 7.8685838771982}}
history: {u'6d': 0.25, u'1w': 0.25, u'1y': 0.25, u'1m': 0.25, u'6m': 0.25, u'2d': 0.25, u'at': 1.25, u'3m': 0.25, u'5d': 0.25, u'4d': 0.25, u'1d': 0.25, u'3d': 0.25}
added_on: 1331246834
cited_by_accounts_count: 2
